Last updated: April 25, 2026
Who Supplies Enzalutamide and What Do They Provide?
Enzalutamide is manufactured and supplied through a multi-tier API and finished-dose supply chain. The practical supplier universe for downstream users falls into two buckets: (1) API makers that sell enzalutamide active pharmaceutical ingredient, and (2) finished-dose manufacturers that supply tablets/capsules (typically under branded or licensed generic programs).
Which companies supply enzalutamide API?
The enzalutamide API market is served by major generic and specialty chemical manufacturers that provide material for tablets and caps. The supplier set is not static because DMF/CEP coverage changes by site, and firms often qualify multiple alternate sources.
Common API supplier categories used in enzalutamide supply chains
- Generic API manufacturers with DMF registrations covering enzalutamide synthesis and purification
- Contract manufacturers that supply API under license or tolling arrangements
- Intermediates-focused chem suppliers that supply key enzalutamide synthesis intermediates to API makers
Actionable note for procurement teams: for enzalutamide, the decisive factor is not brand names but approved manufacturing sites (DMF/CEP), site-specific compliance history, and batch release availability for the exact grade and specification used by the finished-dose holder.
Which companies supply finished-dose enzalutamide (tablets/caps)?
Finished-dose supply is divided across the originator brand supply and multiple licensed generics, with manufacturers changing by country tender cycles and wholesaler allocations.
Finished-dose supply chain structure
- Originator (brand) supply: branded enzalutamide tablets produced under the originator’s commercial manufacturing network
- Licensed generics: tablet manufacturers producing enzalutamide under specific regulatory filings and quality systems
- Wholesaler distribution: channel partners who hold inventory and manage country-specific labeling and packaging
What does “supplier” mean in enzalutamide procurement?
For investment-grade procurement or R&D sourcing, “supplier” must be treated as a set of contracts across the chain:
| Supply layer |
What you buy |
What governs qualification |
| API |
Enzalutamide API (and sometimes enzalutamide polymorph-specific grade) |
DMF/CEP acceptance, impurity profile, residual solvent and elemental specs, process reproducibility |
| Intermediates (when applicable) |
Key intermediates used in enzalutamide synthesis |
Change control, route consistency, spec alignment to API DMF |
| Finished dose |
Enzalutamide tablets (packaged for market) |
Marketing authorization alignment, stability program, packaging release specs, GMP history |
How to map enzalutamide suppliers to your regulatory use case
1) If you are buying API for internal formulation
- Require proof of the API manufacturing site used by the supplier (DMF site code or CEP holder)
- Lock the API specification: impurities, polymorph controls (if applicable), particle size/flow parameters, residual solvents
2) If you are sourcing finished dose
- Decide whether you need the branded product or a specific regulatory filing route (generic equivalent)
- Require batch-level CoA and stability-supporting data consistent with your market’s registration dossier
Competitive landscape: how suppliers typically position
Enzalutamide supplier competition usually plays out on:
- Regulatory acceptance (DMF/CEP coverage)
- Cost and yield of the chemical route used at scale
- Capacity stability (ability to deliver without multi-month lead time spikes)
- Impurity control versus tighter specification constraints imposed by finished-dose holders
Key supplier facts you can operationalize
Procurement short-list criteria for enzalutamide
- Approved API manufacturing site (DMF/CEP coverage for the intended market)
- Consistent impurity profile relative to the finished-dose holder’s target specs
- Demonstrated ability to supply through multi-batch coverage windows
- Batch release documentation readiness (CoA format, analytical method alignment)
Key Takeaways
- Enzalutamide supply is executed through API manufacturing sites and finished-dose tablet manufacturers, with qualification governed by DMF/CEP and site-specific compliance.
- The most actionable “supplier list” for enzalutamide procurement is the set of approved manufacturing sites that match your grade, specification, and market authorization needs, not generic brand or storefront identities.
- Supplier risk concentrates in site changes, DMF updates, and release lead time, so contract terms should bind to site and specification, not just price.
FAQs
1) Who are the main enzalutamide API supplier types?
API supply typically comes from DMF/CEP-registered generic API manufacturers and licensed/toll API manufacturers supporting commercial finished-dose makers.
2) How do finished-dose suppliers differ from API suppliers for enzalutamide?
Finished-dose suppliers provide tablets packaged for market and qualify via marketing authorization and finished-dose GMP. API suppliers qualify via API DMF/CEP acceptance and API spec compliance.
3) What matters most when selecting an enzalutamide supplier?
The binding factors are approved manufacturing site, exact specification/impurity profile, and repeatable batch release availability.
4) Do enzalutamide suppliers change often?
Yes. Enzalutamide supply chains evolve as manufacturing sites, filings, and regulatory authorizations shift by region and by product lifecycle.
5) What documents are typically required for supplier qualification?
At minimum: CoA, GMP statements, impurity spec details, residual solvent and elemental compliance, and DMF/CEP or marketing authorization linkage for the intended market.
References
[1] European Medicines Agency (EMA). European Public Assessment Reports (EPAR) for enzalutamide-containing medicinal products. https://www.ema.europa.eu/
[2] U.S. Food and Drug Administration (FDA). Drug Approval Package and product labeling for enzalutamide products (e.g., NDA review documents and labeling links where available). https://www.fda.gov/
[3] World Health Organization (WHO). WHO International Nonproprietary Names (INN) and supporting information. https://www.who.int/teams/health-product-policy-standards-and-nomenclature/inn
